Radnostix, Inc. Reports Positive Growth Amid Challenges in Q3 2026 Financial Results

Radnostix, Inc. Reports Financial Outcomes for Q3 2026



Radnostix, Inc., formerly known as International Isotopes Inc., has announced its financial performance for the third quarter and the first nine months of fiscal year 2026. The company specializes in radioisotope technologies intended for medical, industrial, and research purposes. This report highlights the salient points from their quarterly results, which reflect both successes and challenges across their various product lines.

Financial Performance Overview



For the third quarter ended September 30, 2026, Radnostix recorded total revenue of $2.57 million, marking a decline of 22% compared to the $3.28 million generated in the same quarter last year. Over the first nine months of 2026, revenues dropped 25% to $7.62 million from $10.17 million in the prior year. This downturn was largely attributed to delays in significant Cobalt Products contracts, awaiting amendments from the Nuclear Regulatory Commission (NRC), and a decrease in sales of Calibration Reference Products due to a global shortage of cobalt-57 raw material. Positive developments were noted in the Theranostics Products segment, which achieved a 15% increase in sales over the previous year.

Despite revenue declines, the company's gross profit for Q3 amounted to $1.51 million, maintaining a healthy gross margin of 59%. For the nine-month period, gross profit was $4.02 million, down from $6.11 million in 2025, primarily influenced by the impact of two voluntary product recalls executed earlier in the year. Operating expenses for Q3 increased by 8% to $2.30 million due to rising professional service costs and heightened activity in the Medical Devices sector.

Net Loss and Cash Position



Radnostix reported a net loss of $0.84 million for the third quarter, a notable increase from the $0.20 million loss observed during Q3 of 2025. Over the nine months, the net loss expanded to $3.07 million compared to $0.48 million in the same period last year. The cash and cash equivalents at the end of September 2026 totaled $0.71 million, a decrease from $1.70 million at the end of 2025. Additionally, the company had $1.53 million in restricted cash allocated to NRC financial assurance.

In October, the company took a significant step to enhance liquidity by securing a $1.0 million revolving line of credit with Bank of Commerce, with a term of twelve months at the prime rate of interest.

Segment Highlights



Theranostics Products



The Theranostics segment delivered revenues of $1.71 million in Q3, representing a 15% year-over-year increase, while nine-month revenues were $4.18 million, a decline of 19%. Segment income slightly increased to $0.67 million in Q3, benefiting from a rise in customer volume. However, the nine-month decline can be attributed to lost revenues from recalls. The segment saw success with the submission of a Type II Drug Master File to the FDA for Sodium Iodide I-131, supporting a client's new drug application.

Calibration Reference Products



This segment saw revenues of $0.74 million in the third quarter, down 23%, with a total of $2.68 million for the nine months, also reflecting a 19% decrease. A global interruption in the supply of cobalt-57 impacted sales and led to a backlog of approximately $300,000. However, the company successfully resumed shipments of gadolinium-153 calibration products after a multi-year gap.

Medical Devices



The Medical Devices segment reported revenues of only $0.04 million for Q3, down 44%, and $0.17 million for the nine months, down 6%. The company plans to market its recently acquired assets under the Lara Detection brand. The roll-out of the EasyFill system is projected for Q1 2027, along with initial plans for the commercialization of RadVent products.

Cobalt Products



Revenues from Cobalt Products plummeted by 88% in Q3, with only $0.09 million reported. This was due to contract delays related to awaiting NRC amendments, causing a delay in substantial sales previously slated for the second half of 2026, which have now shifted to 2027.

Fluorine Products



This segment reported no revenue for the quarter or nine-month period. However, expenses were recorded related to the pending asset sale of Fluorine Products, principally to Nano Nuclear Energy, a move expected to allow Radnostix to concentrate on its core radioactive isotope and medical device businesses once finalized.

Looking Ahead



Management is focused on finalizing the DUF6 asset sale while improving their backlog of cobalt-57 products. They aim to sustain growth in Theranostics, advance medical device commercialization, and practice disciplined cost management moving into Q4 and beyond. The results for Q3 emphasize the resilience of Radnostix, showcasing a revival in certain segments even in the face of significant challenges.

Topics Business Technology)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.